Lung Cancer Among Non-Smokers Increasing
“Rates of lung cancer diagnoses among people who have never smoked are rising, according to the World Health Organization’s cancer agency. The International Agency for Research on Cancer (IARC) estimates that lung cancer is now the fifth highest cause of cancer deaths worldwide among people who have never smoked. In particular, this demographic is almost exclusively experiencing adenocarcinoma, one of four primary sub-types of the disease.”
FDA Grants Breakthrough Device Designation to Serial CTRS AI Model for NSCLC
“Key Takeaways: Serial CTRS, an AI-based tool, stratifies NSCLC patients into high- or low-risk mortality categories, enhancing personalized care. The tool demonstrated improved overall survival predictions over standard methods in a multi-institutional study.”
Weakness in lung cancer’s defenses found—an enzyme that boosts cancer cell metabolism
“Lung cancer is a particularly challenging form of cancer. It often strikes unexpectedly and aggressively with little warning, and it can shapeshift in unpredictable ways to evade treatment.”
Intricacies of EGFR-Mutated NSCLC Care From the Patient Perspective
“In the constantly evolving field of EGFR-mutated NSCLC, physicians, nurses, patients, and caregivers face new questions as efficacy and safety data improve.”
Genetic Sensitivity to Stress: A Possible Link to Lung Cancer Risk
“It’s common knowledge that stress can affect physical and mental health, but does it impact the chance of developing lung cancer? The answer might be yes, according to a study published last month in JAMA Network Open. The results point to a possible connection between stress sensitivity and lung cancer risk, with individuals who are genetically more sensitive to stress and adversity possibly facing a higher risk of developing lung cancer.”
AI/ML-Based Software Improves Diagnostic Accuracy in Lung Cancer
“Eyonis™ Lung Cancer Screening (LCS), a proprietary artificial intelligence (AI)/machine learning–based computer-aided detection (CADe)/diagnosis (CADx) software as a medical device, has met the primary end point of the multi-case, multi-reader, retrospective RELIVE trial (NCT06751576), according to a press release from the developer, Median Technologies.”
Why PD-L1 expression varies between studies of lung cancer: results from a Bayesian meta-analysis
“PD-L1 expression is an important biomarker for the management of non-small cell lung cancer (NSCLC) but has been highly heterogeneous across studies. We developed a statistical model to reconcile conflicting estimates of PD-L1 prevalence by accounting for between-study variation in test sensitivity, specimen age, and laboratory count. In doing so, we obtained refined estimates for PD-L1 expression prevalence and identified differences by histological subtype, mutational status, and stage.”
Video:
Sublobar Resection in Early-Stage NSCLC: Thoracic Surgeon Shares Insights From New Research
“Robert E. Merritt, MD, MBA, FACS, of The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, joined Lung Cancers Today to discuss key takeaways from his research on sublobar resection in early-stage non–small cell lung cancer (NSCLC) for both patients and health care professionals.”
